Hamps Bio Limited (BSE: 544312)
Health Care · Pharmaceuticals · IN
Rs24.50
+0.49% today · -13.5% 1Y
Hamps Bio Limited (BSE: 544312) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.23M.
Over the last twelve months the share price has lost 13.5%, trading between 13.36 and 30.01.
Tweenvest scores Hamps Bio Limited across four factors: quality 47/100, value 54/100, growth 55/100. Its strongest factor is growth.
544312 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.23M
- Revenue (TTM)
- $903.81K
- P/E
- —
- EPS
- -0.85
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- Rs30.01
- 52-week low
- Rs13.36
- Avg volume (3M)
- —
- Shares outstanding
- 8.71M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,199.25 | -2.79% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.42 | -1.00% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.02 | -1.55% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.40 | -0.60% |
Figures last refreshed Aug 18, 2026.